

Reference:	FOI.9689.22
Subject:	Patients treated with specific medications
Date of Request:	22 August 2022

Requested:

1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the treatments listed below:
 - Revolade (eltrombopag)
 - Nplate (romiplostim)
 - Doptelet (avatrombopag)
 - Tavallesse (fostamatinib)
2. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?
3. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:
 - rituximab
 - mycophenolate mofetil
 - surgery (splenectomy)
4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients that have been treated with the listed medications, for any disease, during the period 1 February to 31 July 2022.

Medication	Number
Revolade (eltrombopag)	22
Nplate (romiplostim)	24
Doptelet (avatrombopag)	*
Tavallesse (fostamatinib)	0

2. The UHB confirms that forty-eight (48) patients have been treated for immune thrombocytopenia (ITP), during the period from 1 February to 31 July 2022.
3. The UHB provides, within the table below, the number of patients that have been treated with the listed medications for ICT, during the period from 1 February to 31 July 2022.

Medication	Number
Rituximab	*
Mycophenolate mofetil	6
Surgery (splenectomy)	0

4. The UHB confirms that it is participating in the UK ITP Registry trial and has eight (8) patients enrolled.

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact numbers, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA.

This information is protected by the Data Protection Act 2018 and the UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/UK GDPR define personal data as data which relates to a living individual who can be identified solely from that data, or from that data and other information, which is in the possession of the data controller.